Latest Viral structural proteins Stories
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
New data from a number of clinical trials presented for the first time at the International Liver Congress™ 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.
New tool to help identify areas for increased education and screening for hepatitis C WASHINGTON, July 28, 2011 /PRNewswire-USNewswire/ -- In recognition of World Hepatitis Day, the National Minority Quality Forum today launched the Hepatitis C Index, a novel resource for mapping hepatitis C (http://www.maphepc.com).
The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection.
Researchers study flu proteins in-depth to identify virus vulnerabilities.
BOSTON, Nov. 1, 2010 /PRNewswire/ -- Researchers studied the treatment of pregnant women with hepatitis B virus (HBV) with Telbivudine in their second to third trimesters.
WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program.
Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis.
Research published this week in PLoS Medicine finds that the global spread of Hepatitis C virus (HCV) coincided with widespread use of transfused blood and with the expansion of intravenous drug use but slowed before wholesale implementation of anti-HCV screening.